3,635 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by R Squared Ltd

R Squared Ltd purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 3,635 shares of the medical research company’s stock, valued at approximately $1,474,000. Thermo Fisher Scientific makes up 0.8% of R Squared Ltd’s investment portfolio, making the stock its 17th largest holding.

Several other hedge funds also recently added to or reduced their stakes in TMO. Brighton Jones LLC boosted its holdings in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. GAMMA Investing LLC lifted its stake in Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock valued at $2,419,000 after buying an additional 877 shares during the last quarter. Consolidated Portfolio Review Corp grew its position in Thermo Fisher Scientific by 9.1% during the 1st quarter. Consolidated Portfolio Review Corp now owns 683 shares of the medical research company’s stock worth $340,000 after purchasing an additional 57 shares during the last quarter. Finally, Strategic Investment Advisors MI raised its stake in shares of Thermo Fisher Scientific by 17.3% during the first quarter. Strategic Investment Advisors MI now owns 1,005 shares of the medical research company’s stock worth $500,000 after purchasing an additional 148 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.8%

TMO opened at $571.94 on Friday. The stock’s 50 day moving average price is $502.38 and its 200 day moving average price is $452.23. The stock has a market cap of $215.97 billion, a P/E ratio of 33.04, a P/E/G ratio of 3.25 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the company earned $5.28 EPS. Thermo Fisher Scientific’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,666 shares of company stock valued at $13,990,971. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on TMO. Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, October 12th. HSBC restated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wells Fargo & Company increased their price target on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $595.75.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.